Remibrutinib is an Orally Active BTK Inhibitor for Chronic Urticaria Research
Remibrutinib is a potent and orally active BTK inhibitor for Chronic urticaria (CU) research.
I-287 is an Orally Active PAR2 Inhibitor for Inflammation Research
Effect of I-287 on intracellular signaling pathways induced by the two human PAR2 agonists, Trypsin, and SLIGKV-NH2.
GLPG2534 is an Orally Active IRAK4 Inhibitor for Inflammatory Skin Diseases Research
Kinases typically integrate signaling events down-stream of multiple cytokine receptors. Hence, kinase inhibitors distinguish themselves from cytokine-targeted biologicals by their capacity to modulate multiple signaling pathways simultaneously. IL-1 receptor (IL-1R)–associated…
Tapinarof is a Natural Aryl Hydrocarbon Receptor (AhR) Agonist
Tapinarof (GSK2894512) is a naturally-derived small molecule produced by bacterial symbionts of entomopathogenic nematodes. Especially, Tapinarof displays significant efficacy in psoriasis and atopic dermatitis (AD) modls. Psoriasis vulgaris is a…
Secukinumab (AIN457) is a Human Monoclonal Antibody Targeted against IL-17A
Interleukin-17 family (IL-17 family) is a pro-inflammatory cystine node cytokine family. After binding to the receptor, IL-17 can activate several signal cascades, leading to the induction of chemokines. As chemokines,…
LEO 39652 is a Dual-Soft PDE4 Inhibitor
Atopic dermatitis (AD) is a chronic inflammatory skin disease. the characterizes of AD are eczematous lesions and intense itching. The immune activation of AD mainly due to Th2 cytokines (IL4,…
BMS-986202 is an Orally Active Tyk2 Inhibitor that Binds to Tyk2 JH2
Tyrosine kinase 2 (Tyk2) is a non-receptor tyrosine kinase belonging to the Janus kinase (JAK) family. Specifically, the mammalian JAK family has four members: JAK1, JAK2, JAK3, and Tyk2. JAK…
BMS-986251 is an Orally Active and Selective RORγt Inverse Agonist
Retinoic acid-related orphan receptor γt (RORγt) is a nuclear hormone receptor (NHR) and belongs to the RORγ family. It exists in the thymus and contributes to the differentiation of CD4+T…
CCG-203971 is a Second-Generation RhoA/MRTF-A Inhibitor with Antifibrotic Effect
Metastasis is the major driver in cancer-related deaths. Metastases involve dysregulation of numerous cellular processes. Importantly, blockade of RhoC prevents cellular invasion in breast and prostate cancer models. Especially, RhoA…
AS2863619, a Foxp3 Inducer, is an Orally Active CDK8/19 Inhibitor
AS2863619 is a potent, orally active cyclin-dependent kinase 8 (CDK8) and CDK19 inhibitor with IC50s of 0.61 nM and 4.28 nM, respectively. Firstly, in vitro, AS2863619 is a potent Foxp3 inducer in Tconv cells. AS2863619…